The prevalence and accumulation of main cardiometabolic risk factors among the finnish adult population at different levels of lp(a)

4 April 2025 (10:00 - 10:45)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Professor Pekka Jousilahti

National Institute for Health and Welfare (THL), Helsinki (Finland)

4 More presentations in this session

Presentation thumbnail

Does the length of evolocumab use contribute to myocardial infarction associated hospital readmissions in patients with ACS?: a single center real world evidence from ELAINE

Doctor O. Wani (Flagstaff, US)

Abstract Slides

Presentation thumbnail

Statin intolerance in a real word setting of Italian cardiology centers: data from the BRING-UP Prevention study

Doctor S. Di Fusco (Rome, IT)

Abstract Slides

Presentation thumbnail

Deficient perceptions and practices concerning elevated lipoprotein(a) among specialists in Singapore

Doctor W. Loh (Singapore, SG)

Abstract Slides

Presentation thumbnail

A collaborative working project in primary care: optimising lipid lowering therapies for secondary prevention in high risk patients

Doctor J. Ward (Westbury, GB)

Abstract Slides

Access the full session

Session thumbnail

Dyslipidaemia management in 2025: status quo and best practice (1)

The Event

Event poster

ESC Preventive Cardiology 2025

4 April 2025 10:00 CET

You may be interested in

Congress Presentation

Lipoprotein(a), are its levels really invariable?

Congress Presentation

Lipoprotein(a) and referrals to a specialist lipid clinic

Congress Presentation

Review on clinical strategies for managing patients with elevated Lp(a): Cost-effectiveness of Lp(a) testing and awareness of lifestyle changes via Public Health Policy in absence of targeted therapy

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources